Rabbit Complement in the Lymphocytotoxicity Test

Ferrone, Soldano

doi:10.1111/j.1399-0039.1977.tb01111.x

Cited by 13 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The antibody anti- Absorption studies were also performed on serum 16.16. As already mentioned, the TO 31 cells did not react in cytotoxicity teats with the serum; nonetheless, these cells were able to absorb from the serum the component anti-TO 40, HL-A1 1, thus demonstrating the CYNAP phenomenon (CYtotoxicity Negative, Absorption Positive; Ferrone et al 1967). By contrast, cells TO 31-negative, TO 30-positive were not able to remove by absorption any component of the serum.…”

Section: Resultsmentioning

confidence: 78%

Identification of Two Determinants Included in “Antigen” HL‐A‐10 (TO 31 and TO 40) and of a New Family of Cross‐reacting Specificities (HL‐A1,11, TO 30,31,40)

et al. 1971

View full text Add to dashboard Cite

A new family of cross‐reacting HL—A specificities is described. Sera obtained from a multiparous woman and four polytransfused individuals identify three antigenic determinants belonging to the first HL—A segregant series: TO 30 (gene frequency .0446), TO 31 (gene frequency .0150), and TO 40. Serological, familial, and population analysis shows that (A) the specificities TO 31 and TO 40 are included in HL—A10; (B) TO 30 is probably identical to Ao 28 (from Amos); (C) TO 30, TO 31, TO 40, HL—A1, and HL—A11 are a group of cross‐reacting specificities of the first HL—A series.

show abstract

Section: Resultsmentioning

confidence: 78%

Identification of Two Determinants Included in “Antigen” HL‐A‐10 (TO 31 and TO 40) and of a New Family of Cross‐reacting Specificities (HL‐A1,11, TO 30,31,40)

et al. 1971

View full text Add to dashboard Cite

show abstract

“…Moreover, such effect is not human specific as retrieved in the CDC-XM assay, which uses rabbit sera as the source of complement fractions ( 13 ). Rabbit and human complement activation present differences, which may explain the partial effect reported in the CDC-XM assay as compared to the clear dose-effect found on CH50 and AP50/AH50 assays as well as on the formation of C3d ( 22 , 23 ). Of note and not tested in this study, the amino sequence of the C3 ortholog from annelid is 29% identical with its human counterpart ( 24 ), supporting a role for M101 to regulate in vivo the level of C3 convertase, and in turn complement pathway activation, in Arenicola marina .…”

Section: Discussionmentioning

confidence: 92%

The oxygen carrier M101 alleviates complement activation, which may be beneficial for donor organ preservation

Puissant‐Lubrano

Bouthemy²,

Congy‐Jolivet

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

During organ transplantation, ischemia/reperfusion injury and pre-formed anti-HLA antibodies are the main cause of delayed graft function and recovery through the activation of the complement system. By supplying oxygen during transplantation, M101 is suspected to avoid complement activation, however, a direct effect exerted by M101 on this pathway is unknown. This was tested by using functional assays (lymphocytotoxic crossmatch test, C3d Luminex-based assay, 50% complement hemolysis [CH50], and 50% alternative complement pathway [AP50/AH50]), and quantitative assays (C3, C3a, C4, C5, C5a, C6, C7, C8, C9 and sC5b-9). M101 interferes with the anti-HLA lymphocytotoxic crossmatch assay, and this effect is complement-dependent as M101 inhibits the classical complement pathway (CH50) in a dose-dependent and stable manner. Such inhibition was independent from a proteolytic effect (fractions C3 to C9) but related to a dose-dependent inhibition of the C3 convertase as demonstrated by exploring downstream the release of the anaphylatoxins (C3a and C5a), C3d, and sC5b-9. The C3 convertase inhibition in the presence of M101 was further demonstrated in the AP50/AH50 assay. In conclusion, the use of M101 avoids the activation of the complement pathway, which constitutes an additional advantage for this extracellular hemoglobin to preserve grafts from ischemia/reperfusion injury and preformed anti-HLA antibodies.

show abstract

“…The first complemcnt (batch A) was a commercial low-tox (not absorbed) mixture of about 200 rabbit sera with complement activity suitable to detect alloimmune-anti-H-2 antibodies. To enhance the sensitivity of the cytotoxic assay, rabbit complement with sublytic amounts of rabbit xeno-cytotoxins (nonspecific, xeno-reactive lymphocytotoxins) was recommended (Ferrone 1977) presuming the synergistic effect of the two antibodies. Thc presence of xeno-cytotoxins in complcmcnt is considered to be essential for the detection of MHC-specific antibodies in microlymphocytotoxicity tests (Kennett ct al.…”

mentioning

confidence: 99%

“…Thc presence of xeno-cytotoxins in complcmcnt is considered to be essential for the detection of MHC-specific antibodies in microlymphocytotoxicity tests (Kennett ct al. 1976, Ferrone 1977, Ciossett et a]. 1978, Majsky 1980.…”

mentioning

confidence: 99%

Frequency of naturally occurring H‐2‐specific antibodies in mouse sera monitored by “superreactive” rabbit complement

ÇErná‐Provaznik

Iványi

1985

Tissue Antigens

View full text Add to dashboard Cite

show abstract

Rabbit Complement in the Lymphocytotoxicity Test

Cited by 13 publications

References 13 publications

Identification of Two Determinants Included in “Antigen” HL‐A‐10 (TO 31 and TO 40) and of a New Family of Cross‐reacting Specificities (HL‐A1,11, TO 30,31,40)

Identification of Two Determinants Included in “Antigen” HL‐A‐10 (TO 31 and TO 40) and of a New Family of Cross‐reacting Specificities (HL‐A1,11, TO 30,31,40)

The oxygen carrier M101 alleviates complement activation, which may be beneficial for donor organ preservation

Frequency of naturally occurring H‐2‐specific antibodies in mouse sera monitored by “superreactive” rabbit complement

Contact Info

Product

Resources

About